This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Corxel Pharmaceuticals, a New Jersey-based biotechnology company, announced Thursday it raised $287 million in a Series D1 funding round meant to push an obesity drug into further testing. Corxel gained development rights to its lead program, an oral GLP-1 medicine called CX11, from the Chinese drugmaker Vincentage in 2024. CX11 is in mid-stage t ...